A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors
A Phase Ib/II, Multicenter, Open-Label Study of Safety, Tolerability and Efficacy of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Yunpeng Jing
- Phone Number: +86-0518-82342973
- Email: yunpeng.jin.yj1@hengrui.com
Study Contact Backup
- Name: Hao Shen
- Phone Number: +86-021-61053363
- Email: hao.shen@hengrui.com
Study Locations
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200032
- Recruiting
- Fudan University Shanghai Cancer Center
-
Principal Investigator:
- Xianjun Yu
-
Contact:
- Xianjun Yu
- Phone Number: +86-021-64175590
- Email: yuxianjun@fudanpci.org
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Voluntary participation and written informed consent.
- 18-75 years older, no gender limitation.
- Eastern Cooperative Oncology Group (ECOG) score: 0-1.
- With a life expectancy ≥ 12 weeks.
- Patients with advanced solid tumors confirmed by cytology or histology who have failed or are intolerant to standard treatment and have no standard treatment.
- Be able to provide fresh or archived tumour tissue.
- At least one measurable lesion according to RECIST v1.1.
- Adequate bone marrow and organ function.
- Contraception is required during clinical trials, and pregnancy tests must be negative for women of childbearing age within 7 days before the first dose.
Exclusion Criteria:
- There are components of neuroendocrine carcinoma or sarcoma in the histopathological type.
- Had received chemotherapy, immunotherapy, targeted therapy, anti-tumor traditional Chinese medicine or other clinical research drugs within 4 weeks prior to the first administration of the study; Palliative radiotherapy was received within 2 weeks before the first administration.
- Live attenuated vaccines are used within a certain period of time before the first medication as stipulated in the plan, or it is expected that such vaccines will be needed during the treatment period.
- Having undergone major surgeries other than diagnosis or biopsy within 28 days prior to the first administration.
- Previously received antibody-drug conjugate therapy containing topoisomerase I inhibitors.
- Currently participating in other clinical studies or taking medication for the first time less than 4 weeks after the end of the previous clinical study.
- Suffering from other active malignant tumors within 3 years or at the same time.
- Symptomatic or active central nervous system tumor metastasis.
- Accompanied by uncontrolled tumor related pain.
- Subjects who have experienced severe infections within 30 days prior to their first medication use.
- History of interstitial pneumonia/non infectious pneumonia requiring hormone therapy in the past.
- AE caused by previous anti-tumor treatment has not recovered to CTCAE v5.0 level evaluation ≤ 1.
- Active hepatitis B or active hepatitis C.
- Clinically significant bleeding symptoms or significant bleeding tendency occurred within 1 month before the first medication.
- Moderate and severe ascites with clinical symptoms; Uncontrolled or moderate to excessive pleural effusion and pericardial effusion.
- Uncontrollable mental illness and other conditions known to affect the completion of the study process, such as alcohol, drug or substance abuse, and criminal detention.
- Per the investigator's judgment, there are any other circumstances that may increase the risk of participating in the study, interfere with the study results, or make participation in the study inappropriate.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: SHR-4375 Injection in Combination With Other Antitumor Therapies Group
|
SHR-4375 injection in combination with other antitumor therapies.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Dose limiting toxicity (DLT).
Time Frame: 3 weeks.
|
3 weeks.
|
|
Recommended phase II dose (RP2D).
Time Frame: From screening period up to study completion, an average of 1 year.
|
From screening period up to study completion, an average of 1 year.
|
|
Adverse events (AEs).
Time Frame: From screening period up to study completion, an average of 1 year.
|
From screening period up to study completion, an average of 1 year.
|
|
Objective response rate (ORR).
Time Frame: From screening period up to study completion, an average of 1 year.
|
From screening period up to study completion, an average of 1 year.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Disease control rate (DCR)
Time Frame: From screening period up to study completion, an average of 1 year.
|
From screening period up to study completion, an average of 1 year.
|
|
|
Duration of response (DoR)
Time Frame: From screening period up to study completion, an average of 1 year.
|
From screening period up to study completion, an average of 1 year.
|
|
|
Progression-free survival (PFS)
Time Frame: From screening period up to study completion, an average of 1 year.
|
From screening period up to study completion, an average of 1 year.
|
|
|
Drug Resistant Antibody (ADA) to SHR-4375
Time Frame: From screening period up to study completion, an average of 1 year.
|
Immunogenicity: The number of subjects with ADA to SHR-4375, incidence, time of occurrence, duration, etc.
|
From screening period up to study completion, an average of 1 year.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Amino Acids, Peptides, and Proteins
- Proteins
- Organic Chemicals
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Therapeutics
- Drug Administration Routes
- Drug Therapy
- Hydrocarbons
- Cycloparaffins
- Hydrocarbons, Alicyclic
- Hydrocarbons, Cyclic
- Terpenes
- Enzymes and Coenzymes
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal
- Antibodies
- Immunoglobulins
- Immunoproteins
- Blood Proteins
- Serum Globulins
- Globulins
- Coordination Complexes
- Taxoids
- Cyclodecanes
- Diterpenes
- Pyrimidines
- Formyltetrahydrofolates
- Tetrahydrofolates
- Folic Acid
- Pterins
- Pteridines
- Uracil
- Pyrimidinones
- Coenzymes
- Oxaliplatin
- Bevacizumab
- Fluorouracil
- Leucovorin
- Paclitaxel
- Injections
Other Study ID Numbers
Other Study ID Numbers
- SHR-4375-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.